Understand the source comparison
Best Peptides for Epstein-Barr Virus: Research Comparison
Thymalin Thymic epithelial cell restoration, increases naïve T-cell production Corrects the thymic involution that permits EBV reactivation; restores CD4+/CD8+ ratio 10mg SC daily × 10 days, monthly cycles Moderate (Phase II data in viral infections) Strongest
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Thymic epithelial cell restoration, increases naïve T-cell production
- Corrects the thymic involution that permits EBV reactivation; restores CD4+/CD8+ ratio
- 10mg SC daily × 10 days, monthly cycles
- Moderate (Phase II data in viral infections)
- Strongest mechanistic fit for long-term viral suppression; requires zinc cofactor
- KPV
- NF-κB pathway inhibition, reduces inflammatory cytokines
- Blocks the NF-κB activation EBV uses to prevent infected cell apoptosis
- 500–1000mcg SC daily × 4–8 weeks
- Low-Moderate (preclinical + case series)
- Best for symptom management during reactivation; does not reduce viral load directly
- LL-37
- Antimicrobial peptide, disrupts viral envelopes, activates TLR9
- Direct antiviral activity against herpesviruses; enhances dendritic cell function
- 2–5mg intranasal daily (experimental)
- Low (in vitro + animal models)
- Promising dual mechanism but lacks human dosing consensus; delivery method critical
- MK 677
- Ghrelin receptor agonist, increases endogenous GH/IGF-1
- Prevents thymic atrophy, maintains naïve T-cell output over time
- 25mg oral daily long-term
- Moderate (Phase II in aging/immunosenescence)
- Indirect but foundational; works synergistically with thymalin for thymic restoration